Hanne Bak - Zealand Pharma Sr. Director
| ZLDPF Stock | USD 104.20 1.45 1.41% |
Director
Ms. Hanne Heidenheim Bak was appointed Director, Employee Representative at Zealand Pharma AS, effective as of April 19, 2016. She previously held that position at the Company from April 17, 2012 to April 29, 2014. She is Senior Project Director, GI, External Relations and Collaborations and she holds M.Sc. from the Danish University of Pharmaceutical Sciences. Prior to joining Zealand in 2006, Hanne H. Bak worked 8 years as Project Manager of latephase development programs at H. Lundbeck AS, followed by 9 years as Executive Director at the Lundbeck Institute. since 2016.
| Age | 70 |
| Tenure | 8 years |
| Phone | 45 88 77 36 00 |
| Web | https://www.zealandpharma.com |
Zealand Pharma Management Efficiency
The company has return on total asset (ROA) of (0.4816) % which means that it has lost $0.4816 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.4412) %, meaning that it generated substantial loss on money invested by shareholders. Zealand Pharma's management efficiency ratios could be used to measure how well Zealand Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 7 records | DIRECTOR Age | ||
| Gregory Bailey | Biohaven Pharmaceutical Holding | 65 | |
| Julia Gregory | Biohaven Pharmaceutical Holding | 68 | |
| Deb Young | Biohaven Pharmaceutical Holding | N/A | |
| John Childs | Biohaven Pharmaceutical Holding | 79 | |
| Lucie Mondoulet | DBV Technologies | N/A | |
| Michael Heffernan | Biohaven Pharmaceutical Holding | 56 | |
| Robert Hugin | Biohaven Pharmaceutical Holding | 66 | |
Management Performance
| Return On Equity | -1.44 | |||
| Return On Asset | -0.48 |
Zealand Pharma AS Leadership Team
Elected by the shareholders, the Zealand Pharma's board of directors comprises two types of representatives: Zealand Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zealand. The board's role is to monitor Zealand Pharma's management team and ensure that shareholders' interests are well served. Zealand Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zealand Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Henriette Wennicke, Chief Officer | ||
| Lani Morvan, Investor Officer | ||
| Hanne Bak, Sr. Director | ||
| Adam MD, Pres CEO | ||
| Mads Kronborg, Head Communication | ||
| Ravinder Chahil, Sr Counsel | ||
| Danilo Verge, Head Affairs | ||
| Christina Bredal, VP Organization | ||
| Ivan Moller, Chief Officer | ||
| Jens MD, Head Pharmacology |
Zealand Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Zealand Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.44 | |||
| Return On Asset | -0.48 | |||
| Operating Margin | (3.82) % | |||
| Current Valuation | 1.45 B | |||
| Shares Outstanding | 51.28 M | |||
| Shares Owned By Insiders | 0.07 % | |||
| Shares Owned By Institutions | 56.21 % | |||
| Price To Earning | 4.03 X | |||
| Price To Book | 27.79 X | |||
| Price To Sales | 5.19 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Zealand Pink Sheet
Zealand Pharma financial ratios help investors to determine whether Zealand Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zealand with respect to the benefits of owning Zealand Pharma security.